MOMENTA Pharmaceuticals and
Sandoz have been granted a US
temporary restraining order
preventing Watson and Amphastar
Pharmaceuticals, from marketing
or selling Amphastar’s Enoxaparin
Sodium Injection product, a
generic equivalent to Sanofi-aventis’
anti-thrombosis drug Lovenox.
Momenta and Sandoz were
granted FDA approval for their
generic Lovenox in July last year,
and their suit against Watson and
Amphastar claims the latter’s
product infringes Momenta’s
generic Lovenox patent.
The temporary restraining order
expires on 21 October, and Watson
expects to launch the product
during the fourth quarter of 2011
if the plaintiffs’ request for a
preliminary injunction is denied.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Oct 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Oct 11
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.